These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 28083945)

  • 41. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
    Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
    Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
    Buus R; Sestak I; Kronenwett R; Denkert C; Dubsky P; Krappmann K; Scheer M; Petry C; Cuzick J; Dowsett M
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27400969
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma: the M. D. Anderson Cancer Center evidence-based approach.
    Morandi P; Rouzier R; Altundag K; Buzdar AU; Theriault RL; Hortobagyi G
    Cancer; 2004 Oct; 101(7):1482-9. PubMed ID: 15378476
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Sestak I; Buus R; Cuzick J; Dubsky P; Kronenwett R; Denkert C; Ferree S; Sgroi D; Schnabel C; Baehner FL; Mallon E; Dowsett M
    JAMA Oncol; 2018 Apr; 4(4):545-553. PubMed ID: 29450494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Three years' follow-up from the ATAC trial is sufficient to change clinical practice: a debate.
    Aapro MS; Forbes JF
    Breast Cancer Res Treat; 2003; 80 Suppl 1():S3-11; discussion S13-8. PubMed ID: 14535530
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 48. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
    Dubsky P; Filipits M; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Kronenwett R; Brase JC; Gnant M;
    Ann Oncol; 2013 Mar; 24(3):640-7. PubMed ID: 23035151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study.
    Buus R; Sestak I; Barron S; Loughman T; Fender B; Ruiz CL; Dynoodt P; Wang CA; O'Leary D; Gallagher WM; Dowsett M; Cuzick J
    Clin Cancer Res; 2020 Feb; 26(3):623-631. PubMed ID: 31641007
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
    Hillner BE
    Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.
    Jakesz R; Jonat W; Gnant M; Mittlboeck M; Greil R; Tausch C; Hilfrich J; Kwasny W; Menzel C; Samonigg H; Seifert M; Gademann G; Kaufmann M; Wolfgang J;
    Lancet; 2005 Aug 6-12; 366(9484):455-62. PubMed ID: 16084253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.
    Ma CX; Gao F; Luo J; Northfelt DW; Goetz M; Forero A; Hoog J; Naughton M; Ademuyiwa F; Suresh R; Anderson KS; Margenthaler J; Aft R; Hobday T; Moynihan T; Gillanders W; Cyr A; Eberlein TJ; Hieken T; Krontiras H; Guo Z; Lee MV; Spies NC; Skidmore ZL; Griffith OL; Griffith M; Thomas S; Bumb C; Vij K; Bartlett CH; Koehler M; Al-Kateb H; Sanati S; Ellis MJ
    Clin Cancer Res; 2017 Aug; 23(15):4055-4065. PubMed ID: 28270497
    [No Abstract]   [Full Text] [Related]  

  • 54. Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer.
    Bell R; Lewis J
    Curr Med Res Opin; 2007 May; 23(5):1045-51. PubMed ID: 17519070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The Patient's Anastrozole Compliance to Therapy (PACT) Program: a randomized, in-practice study on the impact of a standardized information program on persistence and compliance to adjuvant endocrine therapy in postmenopausal women with early breast cancer.
    Hadji P; Blettner M; Harbeck N; Jackisch C; Lück HJ; Windemuth-Kieselbach C; Zaun S; Kreienberg R
    Ann Oncol; 2013 Jun; 24(6):1505-12. PubMed ID: 23378537
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population.
    Sgroi DC; Sestak I; Cuzick J; Zhang Y; Schnabel CA; Schroeder B; Erlander MG; Dunbier A; Sidhu K; Lopez-Knowles E; Goss PE; Dowsett M
    Lancet Oncol; 2013 Oct; 14(11):1067-1076. PubMed ID: 24035531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of anastrozole across the breast cancer continuum: from advanced to early disease and prevention.
    Nabholtz JM
    Oncology; 2006; 70(1):1-12. PubMed ID: 16439860
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cognitive complaints after breast cancer treatments: examining the relationship with neuropsychological test performance.
    Ganz PA; Kwan L; Castellon SA; Oppenheim A; Bower JE; Silverman DH; Cole SW; Irwin MR; Ancoli-Israel S; Belin TR
    J Natl Cancer Inst; 2013 Jun; 105(11):791-801. PubMed ID: 23606729
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04).
    Takei H; Ohsumi S; Shimozuma K; Takehara M; Suemasu K; Ohashi Y; Hozumi Y
    Breast Cancer Res Treat; 2012 May; 133(1):227-36. PubMed ID: 22234519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.